GlassScriptPhysician profile
Casey A Salcedo
NPI 1699324707
$6,263.56
in general payments reported to CMS, 2019-2025
36 companies · $1,547 in 2025
The $1,547 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,368 · 2022: $1,253 · 2023: $925 · 2024: $1,170 · 2025: $1,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,642.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,023.12 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $995.77 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $548.28 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Otsuka America Pharmaceutical, INC. | $441.74 | 2021-2025 | Rexulti |
| Glaxosmithkline, LLC. | $417.64 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $250.09 | 2021-2025 | Trintellix |
| Sanofi-Aventis U.S. LLC | $246.88 | 2021-2023 | |
| Amgen INC. | $238.49 | 2021-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $202.05 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Lundbeck LLC | $172.56 | 2022-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $167.91 | 2023-2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $159.04 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.51 | 2021-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $138.38 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $138.05 | 2025 | Auvelity |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $119.64 | 2023-2025 | |
| Esperion Therapeutics, INC. | $113.10 | 2021-2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $97.63 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $79.09 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Biohaven Pharmaceutical Holding Company LTD. | $77.14 | 2022 | |
| Exact Sciences Corporation | $70.05 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $55.24 | 2021 | |
| Mylan Specialty L.P. | $48.10 | 2024 | Yupelri |
| Dexcom, INC. | $39.15 | 2024-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $38.85 | 2021 | |
| Janssen Pharmaceuticals, INC | $38.28 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $33.62 | 2022-2023 | Quviviq |
| Verona Pharma, INC. | $33.37 | 2025 | Ohtuvayre |
| Ardelyx, INC. | $25.33 | 2024 | Ibsrela |
| Scilex Pharmaceuticals INC. | $19.67 | 2021 | |
| Avanir Pharmaceuticals, INC. | $19.54 | 2021 | |
| Vanda Pharmaceuticals INC. | $17.62 | 2024 | Fanapt |
| Viatris Specialty LLC | $16.94 | 2025 | Yupelri |
| Shield Therapeutics INC | $14.42 | 2025 | |
| Eisai INC. | $12.72 | 2021 | |
| Cmp Pharma, INC. | $12.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Salcedo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.